用替加环素治疗耐碳青霉烯类肺炎克雷伯菌（CRKP）菌尿症会导致对替加环素产生耐药性。
Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance.
作者信息
van Duin D, Cober E D, Richter S S, Perez F, Cline M, Kaye K S, Kalayjian R C, Salata R A, Evans S R, Fowler V G, Bonomo R A
机构信息
Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.
出版信息
Clin Microbiol Infect. 2014 Dec;20(12):O1117-20. doi: 10.1111/1469-0691.12714. Epub 2014 Dec 12.
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increasing global threat. Here, we describe the prevalence and impact of tigecycline use in a cohort of patients with CRKP bacteriuria nested within a multicentre, prospective study. In the 21-month study period, 260 unique patients were included. Tigecycline was given to 80 (31%) patients. The use of tigecycline during the index hospitalization was significantly associated with the subsequent development of tigecycline resistance in the same patient (OR, 6.13; 95% CI, 1.15-48.65; p 0.03). In conclusion, the use of tigecycline with CRKP bacteriuria is common, and is associated with the subsequent development of tigecycline resistance.
摘要
耐碳青霉烯类肺炎克雷伯菌（CRKP）对全球的威胁日益增大。在此，我们在一项多中心前瞻性研究中，描述了替加环素在一组CRKP菌尿症患者中的使用情况及其影响。在为期21个月的研究期间，共纳入了260例不同患者。80例（31%）患者接受了替加环素治疗。在首次住院期间使用替加环素与同一患者随后出现替加环素耐药性显著相关（比值比，6.13；95%置信区间，1.15 - 48.65；P = 0.03）。总之，在CRKP菌尿症患者中使用替加环素很常见，且与随后出现替加环素耐药性有关。
相似文献
1
Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance.
Clin Microbiol Infect. 2014 Dec;20(12):O1117-20. doi: 10.1111/1469-0691.12714. Epub 2014 Dec 12.
2
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
Antimicrob Agents Chemother. 2011 Dec;55(12):5893-9. doi: 10.1128/AAC.00387-11. Epub 2011 Oct 3.
3
Tigecycline resistance among carbapenem-resistant Klebsiella Pneumoniae: Clinical characteristics and expression levels of efflux pump genes.
PLoS One. 2017 Apr 7;12(4):e0175140. doi: 10.1371/journal.pone.0175140. eCollection 2017.
4
Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.
J Antimicrob Chemother. 2015 Apr;70(4):1203-11. doi: 10.1093/jac/dku495. Epub 2014 Dec 9.
5
Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study.
Transplant Proc. 2014 Nov;46(9):3219-21. doi: 10.1016/j.transproceed.2014.09.160.
6
Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant Klebsiella pneumoniae.
Infect Control Hosp Epidemiol. 2015 Aug;36(8):942-8. doi: 10.1017/ice.2015.118. Epub 2015 May 20.
7
Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract.
Emerg Microbes Infect. 2018 Jul 9;7(1):127. doi: 10.1038/s41426-018-0129-7.
8
Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients.
Transpl Infect Dis. 2015 Dec;17(6):800-9. doi: 10.1111/tid.12450. Epub 2015 Nov 5.
9
[Controlling infection and spread of carbapenems-resistant Klebsiella pneumoniae among burn patients].
Zhonghua Shao Shang Za Zhi. 2015 Feb;31(1):5-8.
10
Roles of and (A) Mutations in Conferring Tigecycline Resistance in Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00391-17. Print 2017 Aug.
引用本文的文献
1
Multisite Infections Caused by Carbapenem-Resistant Klebsiella Pneumoniae: Unveiling the Clinical Characteristics and Risk Factors.
Antibiotics (Basel). 2025 Jul 18;14(7):721. doi: 10.3390/antibiotics14070721.
2
Tracking international and regional dissemination of the KPC/NDM co-producing Klebsiella pneumoniae.
Nat Commun. 2025 Jul 1;16(1):5574. doi: 10.1038/s41467-025-60765-7.
3
Emergence of Tigecycline-Nonsusceptible Carbapenem-Resistant with Metallo-β-Lactamase and Transferable Ceftazidime-Avibactam Resistance in China.
Pathogens. 2025 Mar 4;14(3):253. doi: 10.3390/pathogens14030253.
4
Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria.
Antibiotics (Basel). 2024 Nov 26;13(12):1138. doi: 10.3390/antibiotics13121138.
5
Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan Hospital.
Int J Microbiol. 2023 May 19;2023:8581883. doi: 10.1155/2023/8581883. eCollection 2023.
6
Epidemiological and Antimicrobial Resistant Patterns, and Molecular Mechanisms of Carbapenem-Resistant Infections in ICU Patients.
Infect Drug Resist. 2023 May 9;16:2813-2827. doi: 10.2147/IDR.S410657. eCollection 2023.
7
adaptive antimicrobial resistance in during antibiotic therapy.
Front Microbiol. 2023 Mar 16;14:1159912. doi: 10.3389/fmicb.2023.1159912. eCollection 2023.
8
Multidrug-Resistant Bacteria: Their Mechanism of Action and Prophylaxis.
Biomed Res Int. 2022 Sep 5;2022:5419874. doi: 10.1155/2022/5419874. eCollection 2022.
9
A Longitudinal Nine-Year Study of the Molecular Epidemiology of Carbapenemase-Producing Isolated From a Regional Hospital in Taiwan: Predominance of Carbapenemase KPC-2 and OXA-48.
Front Microbiol. 2022 Mar 11;13:703113. doi: 10.3389/fmicb.2022.703113. eCollection 2022.
10
Clonal spread of carbapenemase-producing Enterobacteriaceae in a region, China.
BMC Microbiol. 2022 Mar 29;22(1):81. doi: 10.1186/s12866-022-02497-y.
本文引用的文献
1
Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.
Antimicrob Agents Chemother. 2014 Jul;58(7):4035-41. doi: 10.1128/AAC.02636-14. Epub 2014 May 5.
2
Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).
Antimicrob Agents Chemother. 2014;58(4):2274-80. doi: 10.1128/AAC.02684-13. Epub 2014 Feb 3.
3
Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin resistance.
J Antimicrob Chemother. 2014 Mar;69(3):632-6. doi: 10.1093/jac/dkt419. Epub 2013 Oct 23.
4
Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2013 Nov;57(11):5743-6. doi: 10.1128/AAC.00827-13. Epub 2013 Aug 26.
5
Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010.
Infect Control Hosp Epidemiol. 2013 Mar;34(3):259-68. doi: 10.1086/669523. Epub 2013 Jan 23.
6
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20. doi: 10.1016/j.diagmicrobio.2012.11.009. Epub 2013 Jan 3.
7
In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline.
J Antimicrob Chemother. 2012 Nov;67(11):2696-9. doi: 10.1093/jac/dks288. Epub 2012 Jul 24.
8
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.
Am J Infect Control. 2008 Jun;36(5):309-32. doi: 10.1016/j.ajic.2008.03.002.
9
Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates.
J Clin Microbiol. 2005 Aug;43(8):4178-82. doi: 10.1128/JCM.43.8.4178-4182.2005.
10
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.
Int J Antimicrob Agents. 1999 Jan;11(1):7-12. doi: 10.1016/s0924-8579(98)00060-0.
Zotero 插件